Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

08-08-2022 | Breast Cancer | ASO Author Reflections

ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer

Authors: Austin D. Williams, MD, MSEd, Andrea V. Barrio, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

The use of neoadjuvant chemotherapy (NAC) in patients with operable breast cancer has increased in the past decade, with the goal of preserving the breast and avoiding axillary lymph node dissection (ALND). Breast cancer incidence is higher in women over the age of 65 years;1 however, older patients undergo NAC less frequently, owing to concerns about medical comorbidities, adverse events, and potentially lower response rates compared with younger women.2 We sought to better understand the clinical benefit and tolerability of NAC among patients ≥ 70 years of age compared with younger women 50–69 years of age. …
Literature
1.
2.
von Waldenfels G, Loibl S, Furlanetto J, et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients—a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018;9(20):15168–79.CrossRef
3.
4.
Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47.CrossRefPubMedPubMedCentral
Metadata
Title
ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer
Authors
Austin D. Williams, MD, MSEd
Andrea V. Barrio, MD
Publication date
08-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12324-3

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

Hepatobiliary Tumors

Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade

ASO Author Reflections

ASO Author Reflections: Chyle Leak after Axillary Node Clearance in Breast Cancer Surgery, a Successful Management Approach from Leading Centres

ASO Visual Abstract

ASO Visual Abstract: Chyle Leak After Axillary Node Clearance in Breast Cancer Surgery: A Rare Complication and a Proposed Management Strategy from the British and Italian Experience

Melanoma

National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma

ASO Author Reflections

ASO Author Reflections: How Immunotherapy Could Change the Management of Responsive Solid Tumors

Breast Oncology

Disparities in Primary Breast Cancer Stage at Presentation Among Hispanic Subgroups